What is Mixed Hyperlipidaemia?

Hyperlipidaemia (also commonly referred to as Dyslipidaemia) is a condition characterised by abnormal levels of total cholesterol, including Low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), or triglycerides (TG), or all concurrently. It may also refer to a lower-than-normal level of high-density lipoprotein cholesterol (HDL-C). Either form may increase the risk of atherosclerosis, which can, in turn, increase the risk of cardiovascular disease in these patients.

How common is it?

According to the Australian Bureau of Statistics, around 8.4% of Australians, or 2.1 million people, had high cholesterol in 2022, and the rates rise steadily with age. This means many adults are living with unhealthy blood fat levels that can quietly increase their risk of heart disease and stroke over time, even if they feel well day to day. Among people aged 75 and older, almost three in ten are affected, underscoring the significant impact of this issue later in life.

Why Focus on Mixed High Cholesterol and Triglycerides?

Heart disease is the leading cause of death worldwide, and high cholesterol plays a big role in that risk. Lowering “bad” cholesterol (LDL) is important, and treatments like statins and other medications help—but even when LDL is well controlled, many people still face residual risk for heart disease.

Why? Because other blood fats, like high triglycerides, lipoprotein(a), and remnant cholesterol, also increase risk. Current treatments don’t fully address these factors, which means there’s still an unmet need for new therapies that work in different ways.

This clinical trial is exploring a new approach that could help reduce these additional risks and improve heart health for millions.

Who can participate?

You may qualify if you:

• Are 18 years or older
• Have high triglycerides (1.69-5.64 mmol/L) and either:
  • High non-HDL cholesterol (2.59 mmol/L or more), or
  • High LDL cholesterol (1.8 mmol/L or more).
• Are willing to give consent and take part in trial procedures.
• Are open to following low-fat diet recommendations provided by the clinical trials team.

This trial will be conducted at our Health Hub Morayfield clinic in Moreton Bay. Eligible participants will be reimbursed for their time on the trial. The trial has been reviewed and approved by an independent Human Research Ethics Committee.

What's involved?

Participants must be able to attend up to 17 visits, including two overnight stays at our Morayfield clinic during the 8.5-month trial period.

This is a placebo-controlled trial, meaning participants will be randomly assigned in a 3:1 ratio to receive either the investigational medication or a placebo.

Procedures and Assessments

• Physical Exam
• Vital Signs
• BMI/Weight/Height
• Medical History
• Drug Screen
• Full Lipid Panel Blood Tests
• 12-Lead ECG
• Administration of investigational medication via injection under the skin.

Where can I find more information?

More information can be requested by contacting the recruitment team on 07 5409 8640. Alternatively, the team will be more than happy to answer any questions you may have when they call.